Maria Kristina Wigenfeldt

Quantovir AB conducts research and development of methods for cancer diagnostics and related business. It develops technology for quantitative measurement of high-risk Human Papillomavirus (HPV) types using deoxyribonucleic acid (DNA)-based detection. It demonstrates that a molecular diagnostic test measuring the quantity, or viral load, of HPV DNA present in cervical specimens can be used to predict a woman's risk of developing cervical cancer. The company was founded by Ulf Gyllensten on February 28, 2001 and is headquartered in Uppsala, Sweden.